Novo Nordisk Licenses Factor XIII Portfolio From ZymoGenetics
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is discussing the pivotal trial program for Factor XIII with FDA following the agreement. Novo Nordisk expects to initiate clinical studies in fibrinolysis-induced bleeding next year.